Registration No. 333-227909
PROSPECTUS SUPPLEMENT NO. 2
as amended by Amendment No. 1 to Form S-1 filed on December 10, 2018,
and as supplemented by Prospectus Supplement No. 1 filed on February 14, 2019)
This Prospectus Supplement No. 2 supplements the prospectus dated December 10, 2018 (the “prospectus”) relating to the offering and resale by the selling stockholders identified in the prospectus of up to 5,830,000 shares of common stock of Isoray, Inc., par value $0.001 per share. This Prospectus Supplement should be read in conjunction with the prospectus which is to be delivered with this Prospectus Supplement. Any statement contained in the prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement. Any statement that is modified or superseded shall not be deemed to constitute a part of the prospectus except as modified or superseded by this Prospectus Supplement.
This Prospectus Supplement is being filed to update and supplement the information in the prospectus with our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed with the Securities and Exchange Commission on May 10, 2019.
Caution Regarding Forward-Looking Information
In addition to historical information, this Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA.
All statements contained in this Form 10-Q, other than statements of historical facts, that address future activities, events or developments are forward-looking statements, including, but not limited to, statements containing the words “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services, developments or industry rankings; any statements regarding future revenue, economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results will conform to the expectations and predictions of management is subject to a number of risks and uncertainties described under Item 1A - Risk Factors beginning on page 20 below that may cause actual results to differ materially.
Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by management will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our business operations. Readers are cautioned not to place undue reliance on such forward-looking statements as they speak only of the Company’s views as of the date the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Critical Accounting Policies and Estimates
The discussion and analysis of the Company’s financial condition and results of operations are based upon its consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, management evaluates past judgments and estimates, including those related to bad debts, inventories, accrued liabilities, derivative liabilities and contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The accounting policies and related risks described in the Company’s annual report on Form 10-K as filed with the SEC on September 26, 2018 are those that depend most heavily on these judgments and estimates. As of March 31, 2019 there had been no material changes to any of the critical accounting policies contained therein.
Overview
Isoray, Inc. is a brachytherapy device manufacturer with FDA clearance and CE marking for a single medical device that can be delivered to the physician in multiple configurations as prescribed for the treatment of cancers in multiple body sites. The Company manufactures and sells this product as the Cesium-131 brachytherapy seed.
The brachytherapy seed utilizes Cesium-131, with a 9.7 day half-life, as its radiation source. The Company believes that it is the unique combination of the short half-life and the energy of the Cesium-131 isotope that are yielding the beneficial treatment results that have been published in peer reviewed journal articles and presented in various forms at conferences and tradeshows.
The Company has distribution agreements outside of the United States. These distributors are responsible for obtaining regulatory clearance to sell the Company’s products in their territories, with the support of the Company. As of the date of this Report, the Company had distributors in Italy, Switzerland, the Russian Federation, and Peru with a nominal amount of reported revenues in these locations during the nine months ended March 31, 2019.
The Company has a supply agreement with The Open Joint Stock Company <<Isotope>>, a Russian company, for the supply of Cesium-131, which was recently extended through December 31, 2019. The Company also has a consignment inventory agreement with MedikorPharma-Ural LLC (“Medikor”) to process the Company’s enriched barium at another nuclear reactor in Russia. The term of this consignment agreement began in November 2017 and is for 10 years. Our source of supply of Cesium-131 from Russia is historically produced using one of two nuclear reactors which supply the irradiation needed for Cesium-131 production. One of the Russian nuclear reactors was shut down from December 2017 until August 2018, and the other Russian nuclear reactor is scheduled to be shut down in the second half of calendar 2019 into 2020. As a result of these scheduled shutdowns, only one of the Company's historic Russian suppliers of Cesium-131 will be available during these periods.
The Company had a third supply agreement to receive irradiated barium from the University of Missouri Research Reactor (“MURR”). However the Company terminated this agreement, effective December, 2018.
Results of Operations
Three months ended March 31, 2019 and 2018 (in thousands):
|
|
Three months ended March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019 - 2018
|
|
|
|
Amount
|
|
|
% (a)
|
|
|
Amount
|
|
|
% (a)
|
|
|
% Change
|
|
Sales, net
|
|
$
|
1,924
|
|
|
|
100
|
|
|
$
|
1,573
|
|
|
|
100
|
|
|
|
22
|
|
Cost of sales
|
|
|
1,045
|
|
|
|
54
|
|
|
|
964
|
|
|
|
61
|
|
|
|
8
|
|
Gross profit
|
|
|
879
|
|
|
|
46
|
|
|
|
609
|
|
|
|
39
|
|
|
|
44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses - proprietary
|
|
|
299
|
|
|
|
16
|
|
|
|
317
|
|
|
|
20
|
|
|
|
(6
|
)
|
Research and development expenses – collaboration agreement, net of reimbursement
|
|
|
-
|
|
|
|
-
|
|
|
|
156
|
|
|
|
10
|
|
|
|
(100
|
)
|
Sales and marketing expenses
|
|
|
645
|
|
|
|
34
|
|
|
|
692
|
|
|
|
44
|
|
|
|
(7
|
)
|
General and administrative expenses
|
|
|
1,099
|
|
|
|
57
|
|
|
|
783
|
|
|
|
50
|
|
|
|
40
|
|
Gain on Equipment Disposal
|
|
|
(1
|
)
|
|
|
(0
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Total operating expenses
|
|
|
2,042
|
|
|
|
106
|
|
|
|
1,948
|
|
|
|
124
|
|
|
|
5
|
|
Operating loss
|
|
|
(1,163
|
)
|
|
|
(60
|
)
|
|
|
(1,339
|
)
|
|
|
(85
|
)
|
|
|
(13
|
)
|
|
(a)
|
Expressed as a percentage of sales, net
|
Nine months ended March 31, 2019 and 2018 (in thousands):
|
|
Nine months ended March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019 - 2018
|
|
|
|
Amount
|
|
|
% (a)
|
|
|
Amount
|
|
|
% (a)
|
|
|
% Change
|
|
Sales, net
|
|
$
|
5,390
|
|
|
|
100
|
|
|
$
|
4,320
|
|
|
|
100
|
|
|
|
25
|
|
Cost of sales
|
|
|
3,222
|
|
|
|
60
|
|
|
|
2,915
|
|
|
|
67
|
|
|
|
11
|
|
Gross profit
|
|
|
2,168
|
|
|
|
40
|
|
|
|
1,405
|
|
|
|
33
|
|
|
|
54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses - proprietary
|
|
|
1,088
|
|
|
|
20
|
|
|
|
914
|
|
|
|
21
|
|
|
|
19
|
|
Research and development expenses – collaboration agreement, net of reimbursement
|
|
|
45
|
|
|
|
1
|
|
|
|
260
|
|
|
|
6
|
|
|
|
(83
|
)
|
Sales and marketing expenses
|
|
|
1,996
|
|
|
|
37
|
|
|
|
1,980
|
|
|
|
46
|
|
|
|
1
|
|
General and administrative expenses
|
|
|
3,173
|
|
|
|
59
|
|
|
|
2,610
|
|
|
|
60
|
|
|
|
22
|
|
Gain on Equipment Disposal
|
|
|
(24
|
)
|
|
|
(0
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Total operating expenses
|
|
|
6,278
|
|
|
|
116
|
|
|
|
5,764
|
|
|
|
133
|
|
|
|
9
|
|
Operating loss
|
|
|
(4,110
|
)
|
|
|
(76
|
)
|
|
|
(4,359
|
)
|
|
|
(101
|
)
|
|
|
(6
|
)
|
|
(a)
|
Expressed as a percentage of sales, net
|
Sales
Changes in sales personnel and implementation of a revitalized sales and marketing strategy in the second quarter of fiscal 2017 continued the ongoing positive sales growth in the third quarter of fiscal 2019 when compared to fiscal 2018 third quarter. Ongoing training and support of new sales personnel has led to not only new customers but also reconnecting with and receiving orders from prior customers.
Three months ended March 31, 2019 and 2018 (in thousands):
|
|
Three months ended March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019 - 2018
|
|
|
|
Amount
|
|
|
% (a)
|
|
|
Amount
|
|
|
% (a)
|
|
|
% Change
|
|
Prostate brachytherapy
|
|
$
|
1,690
|
|
|
|
88
|
|
|
$
|
1,304
|
|
|
|
83
|
|
|
|
30
|
|
Other sales
|
|
|
234
|
|
|
|
12
|
|
|
|
269
|
|
|
|
17
|
|
|
|
(13
|
)
|
Sales, net
|
|
|
1,924
|
|
|
|
100
|
|
|
|
1,573
|
|
|
|
100
|
|
|
|
22
|
|
|
(a)
|
Expressed as a percentage of sales, net
|
Nine months ended March 31, 2019 and 2018 (in thousands):
|
|
Nine months ended March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019 - 2018
|
|
|
|
Amount
|
|
|
% (a)
|
|
|
Amount
|
|
|
% (a)
|
|
|
% Change
|
|
Prostate brachytherapy
|
|
$
|
4,761
|
|
|
|
88
|
|
|
$
|
3,703
|
|
|
|
86
|
|
|
|
29
|
|
Other sales
|
|
|
629
|
|
|
|
12
|
|
|
|
617
|
|
|
|
14
|
|
|
|
2
|
|
Sales, net
|
|
|
5,390
|
|
|
|
100
|
|
|
|
4,320
|
|
|
|
100
|
|
|
|
25
|
|
|
(a)
|
Expressed as a percentage of sales, net
|
Prostate Brachytherapy
Prostate brachytherapy sales were impacted by growing sales to existing and new customers. Also, website improvements and significant investments in product support literature, social media and public relations are increasing the awareness of the Company in the prostate brachytherapy treatment markets providing the Company opportunities to develop new customers and reconnect with past customers.
Management believes growth in prostate brachytherapy revenues will be the result of physicians, payers, and patients increasingly considering overall brachytherapy treatment advantages including costs, better treatment outcomes and improvement in the quality of life for patients, when compared with non-brachytherapy treatments.
Management believes increased pressure to deliver effective healthcare in both terms of outcome and cost drove treatment options, and accordingly improved the Company’s prostate revenues, in the quarter ended March 31, 2019.
Other Sales
Other sales includes, but is not limited to, brain, lung, head/neck, gynecological treatments, and services. Initial applications for these other brachytherapy treatments are primarily used in recurrent cancer treatments or salvage cases that are generally difficult to treat aggressive cancers where other treatment options are either ineffective or unavailable.
These other brachytherapy treatments continue to be subject to the influence of a small pool of innovative physicians who are the early adopters of the technology who also tend to be faculty at teaching hospitals training the next generation of physicians. This causes the revenue created by these types of treatment applications to be more volatile and vary significantly from quarter to quarter. This volatility resulted in the variability in the three and nine months ended March 31, 2019 compared to the prior year.
Cost of sales
Cost of sales consists primarily of the costs of manufacturing and distributing the Company’s products.
Contributing to the three and nine months ended March 31, 2019 and 2018 comparison were increased isotope and other direct materials purchases as well as increased labor to meet production demand due to improved sales. Also contributing to the increase are higher depreciation costs due to completed automation projects placed into service.
Research and development
Research and development – proprietary
Proprietary research and development consists primarily of employee and third-party costs related to research and development activities.
Contributing to the three and nine months ended March 31, 2019 and 2018 proprietary research and development comparison were increases associated with participation in new protocols, device development activities, legal fees relating to patents and trademarks, reallocation of employee costs for employees working on research and development projects, as well as increased consulting costs which were partially offset by reduced software and travel costs.
Research and development – collaborative arrangement
Collaboration arrangement related costs are incurred, shared, and separately stated in connection with a collaborative research and development project with GammaTile, LLC.
Contributing to the three and nine months ended March 31, 2019 and 2018 comparison were decreased costs due to the fact that payments being made pursuant to the collaborative arrangement with GammaTile, LLC were no longer necessary at the same level, as the collaborative arrangement primarily related to work involved in obtaining 510(k) clearance, which has now been obtained. Since the collaborative agreement with GammaTile, LLC terminated during March 2018, the Company and GT Medical Technologies have worked collaboratively to obtain 510(k) clearance and on the design transfer to production without a formal agreement. As such, the costs are no longer shared equally and during the three and nine months ended March 31, 2019 GT Medical Technologies was responsible for more than 50% of the costs.
Sales and marketing expenses
Sales and marketing expenses consist primarily of the costs related to the internal and external activities of the Company’s sales, marketing and customer service functions of the Company. As the Company increasingly focuses on improving sales, the cost associated with marketing and greater staffing continues to increase.
Decreased tradeshow and travel costs are a major factor in the cost comparison for the three months ended March 31, 2019 and 2018 as the Company attended fewer tradeshows in the three months ending March 31, 2019 compared to 2018. Expenses for the nine months ended March 31, 2019 and 2018 did not change materially.
General and administrative expenses
General and administrative expenses consist primarily of the costs related to the executive, human resources/training, quality assurance/regulatory affairs, finance, and information technology functions of the Company.
Contributing to the three months ended March 31, 2019 and 2018 comparison were cost increases associated with payroll due to increased headcount, employee hiring expenses, investor relations, tax audit expense, legal fees, and insurance premiums. During the three months ended March 31, 2019, we accrued approximately $80,000 of expenses relating to the State of Washington Hazardous Substance Tax resulting from a state tax audit, $50,000 accrued based on negotiations with a former consultant, and related professional service fees.
Contributing to the nine months ended March 31, 2019 and 2018 comparison were cost increases associated with payroll due to increased headcount and employee hiring expense, insurance premiums, renewal fees of our CE Mark, legal fees, tax audit expense, and proxy solicitation fees associated with redomiciling the Company to Delaware. These costs were partially offset in the nine months ended March 31, 2019 by decreases associated with public company related expenses as a result of changing some key vendors which resulted in significant savings.
Liquidity and capital resources
The Company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company has historically financed its operations through selling equity to investors. During the nine months ended March 31, 2019 and 2018, the Company used existing cash reserves to fund its operations and capital expenditures (in thousands except current ratio):
|
|
Nine months
|
|
|
|
ended March 31,
|
|
|
|
2019
|
|
|
2018
|
|
Net cash used by operating activities
|
|
$
|
(4,064
|
)
|
|
$
|
(4,264
|
)
|
Net cash (used) provided by investing activities
|
|
|
(1,838
|
)
|
|
|
658
|
|
Net cash provided by financing activities
|
|
|
7,361
|
|
|
|
39
|
|
Net increase (decrease) in cash and cash equivalents
|
|
$
|
1,459
|
|
|
$
|
(3,567
|
)
|
|
|
As of
|
|
|
|
March 31, 2019
|
|
|
June 30, 2018
|
|
Working capital
|
|
$
|
7,096
|
|
|
$
|
3,611
|
|
Current ratio
|
|
|
6.24
|
|
|
|
2.97
|
|
Cash flows from operating activities
Net cash used by operating activities in the nine months ended March 31, 2019 was primarily due to a net loss of approximately $4.05 million, net of approximately $405,000 in adjustments for non-cash activity such as depreciation and amortization expense, gain on equipment disposal, ARO accretion, and share-based compensation. Changes in operating assets and liabilities used approximately $420,000 to fund operating activities; decreases in accounts payable and accrued expenses, accrued payroll and related taxes, accrued vacation and an increase in prepaid expenses and other current assets were partially offset by decreases in accounts receivable and inventory and increases in accrued protocol expense and accrued radioactive waste disposal.
Cash flows from investing activities
Investing activities consisted of transactions related to the purchase and sale of fixed assets, including automation of production processes, as well as the purchase and subsequent maturity of U.S. Treasury Bills. Management will continue to invest in technology and machinery that improves and streamlines production processes and to invest maturing U.S. Treasury Bills in low-risk investment opportunities that safeguard assets and provide greater assurance those resources will be liquid and available for business needs as they arise.
Cash flows from financing activities
Financing activities in the nine months ended March 31, 2019 included payment of preferred dividends and proceeds from sale of common stock, pursuant to a registered direct offering, net (see note 11 to the financial statements), and proceeds from sales of common stock, pursuant to the exercise of options.
Projected 2019 Liquidity and Capital Resources
Operating activities
Assuming no extraordinary expenses occur (whether operating or capital), if management is successful at implementing its strategy of renewed emphasis on driving the consumer to the prostate market, meets or exceeds its annual growth targets of twenty-five percent increase in revenue in fiscal 2019 and this annual growth continues, the Company anticipates reaching cashflow break-even in three to five years. The Company met that target of twenty-five percent increased revenue in the nine months ended March 31, 2019. There is no assurance that targeted sales growth will continue over the next three to five years. However, management is encouraged by the results for the nine months ended March 31, 2019 and by the depth and experience of its restructured sales team.
Capital expenditures
Management has completed the design of a future production and administration facility. If financing is obtained and the facility constructed, it is believed that the new facility will have non-cash depreciation cost equal to or greater than the monthly rental cost of the current facility.
Management is reviewing and implementing changes in all aspects of production operations (including process automation), research and development, sales and marketing, and general and administrative functions to evaluate the most efficient deployment of capital to ensure that the appropriate materials, systems, and personnel are available to support and drive sales.
During the nine months ended March 31, 2019, the Company invested approximately $219,000 in the automation of thirteen production processes, four of which have been placed into service. Through March 31, 2019, the Company has invested approximately $768,000 in these automation projects, and management is expecting to invest approximately $200,000 more over the next 7 months in the remaining projects. This investment is designed to allow the Company to significantly increase the output of Cesium-131 brachytherapy seeds while allowing the Company to decrease the labor costs related to seed production and also improving the overall safety of our operations.
Financing activities
There was no material change in the use of proceeds from our public offering as described in our final prospectus supplement filed with the SEC pursuant to Rule 424(b) on March 24, 2014. Through March 31, 2019, the Company had used the net proceeds raised through the March 2014 offering as described in the public offering. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.
On August 25, 2015, the Company filed a registration statement on Form S-3 to register securities up to $20 million in value for future issuance in our capital raising activities. The registration statement became effective on November 19, 2015, and the SEC file number assigned to the registration statement was 333-206559 and it expired on November 19, 2018.
On July 11, 2018, the Company sold 11,000,000 shares of its common stock at a price of $0.75 per share, for aggregate gross proceeds of $8.25 million, pursuant to the registration statement described above. There was no material change in the use of proceeds from our public offering as described in our prospectus supplement filed with the SEC pursuant to Rule 424(b) on July 11, 2018. Through March 31, 2019, the Company had used the net proceeds raised through the July 11 offering as described in the prospectus supplement. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.
Additionally, the Company issued to the purchasers unregistered warrants to purchase up to 5,500,000 shares of common stock. The warrants have an exercise price of $0.75 per share common stock, are exercisable commencing six months following the issuance date, and expire five and one-half years from the issuance date. If exercised for cash, future exercises of these warrants will provide additional capital to the Company.
On October 19, 2018, the Company filed a Form S-1 registration statement for the registration of 5,830,000 shares of common stock to be received by the investors and representatives of Wainwright on exercise of warrants issued in connection with the registered direct offering completed on July 11, 2018. The Company may receive up to $4,434,375 in gross proceeds solely to the extent the warrants are exercised for cash. The registration statement became effective on December 14, 2018, and the SEC file number assigned to the registration statement is 333-207909.
The Company expects to finance its future cash needs through sales of equity, possible strategic collaborations, debt financing or through other sources that may be dilutive to existing shareholders. Management anticipates that if it raises additional financing that it will be at a discount to the market price and it will be dilutive to shareholders.
Other Commitments and Contingencies
The Company presented its other commitments and contingencies in our Annual Report on Form 10-K for the fiscal year ended June 30, 2018. There have been no material changes outside of the ordinary course of business in those obligations during the quarter ended March 31, 2019 other than those previously disclosed in Note 8 of the interim financial statements contained in this Form 10-Q.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. The Company evaluates its estimates and judgments on an ongoing basis. The Company bases its estimates on historical experience and on various other factors the Company believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Actual results could therefore differ materially from those estimates if actual conditions differ from our assumptions.
During the quarter ended March 31, 2019, there have been no changes to the critical accounting policies and estimates, as discussed in Part II, Item 7 of our Form 10-K for the year ended June 30, 2018.
ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes to the disclosure in the “Quantitative and Qualitative Disclosures about Market Risk Factors” section of our Annual Report on Form 10-K for the year ended June 30, 2018.
ITEM 4 – CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and co-principal financial officers, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rules 13a-14(c) and 15d-14(c) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of March 31, 2019. Based on that evaluation, our principal executive officer and our co-principal financial officers have concluded that the design and operation of our disclosure controls and procedures were effective. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. However, management believes that our system of disclosure controls and procedures are designed to provide a reasonable level of assurance that the objectives of the system will be met.
Changes in Internal Control over Financial Reporting
There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.